Actuate Therapeutics, Inc. Common stock (ACTU) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-03-26

How it makes money

It currently generates no revenue and relies entirely on future clinical success to secure regulatory approvals and commercial sales.

As a clinical-stage biopharmaceutical firm, it earns nothing from product sales. Its future earnings depend on the successful development of its lead candidate, elraglusib, which inhibits the GSK-3β enzyme to treat various cancers. Financial viability requires navigating complex clinical trials, obtaining regulatory approval from agencies like the FDA, and establishing commercialization agreements.

What protects it: the moat

Management claims its competitive advantage rests on patent protection for its licensed GSK-3 inhibitor technology.

It relies on intellectual property exclusively licensed from the University of Illinois-Chicago and Northwestern University. Because it has no approved products, its protection from competition is based on the legal exclusivity of its patents and the clinical status of its drug candidate.

What growth costs

Growth requires massive, ongoing reinvestment into clinical trials and research to advance drug candidates through regulatory stages.

Its operating costs are almost entirely driven by R&D activities, including managing clinical trials for indications like mPDAC and pediatric solid cancers. It must continuously raise capital to fund these trials, as it has no internal cash flow to support its development pipeline.

What could damage it

A failure in clinical trials to meet primary efficacy endpoints would immediately collapse its only value driver.

The business is a binary bet on the efficacy of elraglusib. If trials fail to demonstrate patient survival benefits, it loses its path to regulatory approval and, consequently, its ability to commercialize the drug or attract further funding.

About Actuate Therapeutics, Inc. Common stock

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.

Other companies in Biotechnology